Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes ...

GLP-1 RAs are great medications to help with weight loss and are particularly effective in decreasing “food noise” and the ...

For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric adverse events or worsening ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights ...

Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity.

GLP-1 agonists, medications commonly used for weight loss and type 2 diabetes, may also help reduce alcohol intake — an ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Reductions in alcohol intake were noted in high and low consumers; no significant difference was seen in percentage reductions for men and women.

As weight loss medications like Ozempic continue to gain popular, experts and patients are noticing varying effects of the ...